Antiplatelet agents’-ticagrelol and eptifibatide-safety in experimental colitis in mice | Zendy

Stanko Petrović | Zendy; Milijana Vasiljevska | Zendy; Slobodan Obradović | Zendy; Dino Tarabar | Zendy; Radoje Doder | Zendy; Ivana Majstorović | Zendy; Marijana Petrović | Zendy; Zvonko Magić | Zendy; Bojana CikotaAleksić | Zendy; Nenad Perišić | Zendy; Irina Brcerevic | Zendy; Nebojša Manojlović | Zendy; Nemanja Rančić | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiplatelet agents’-ticagrelol and eptifibatide-safety in experimental colitis in mice

Author(s) -

Stanko Petrović,

Milijana Vasiljevska,

Slobodan Obradović,

Dino Tarabar,

Radoje Doder,

Ivana Majstorović,

Marijana Petrović,

Zvonko Magić,

Bojana CikotaAleksić,

Nenad Perišić,

Irina Brcerevic,

Nebojša Manojlović,

Nemanja Rančić

Publication year - 2020

Publication title -

the turkish journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.404

H-Index - 28

eISSN - 2148-5607

pISSN - 1300-4948

DOI - 10.5152/tjg.2020.19454

Subject(s) - medicine , eptifibatide , hematocrit , colitis , ticagrelor , platelet , gastroenterology , ulcerative colitis , inflammatory bowel disease , hemoglobin , pharmacology , anesthesia , aspirin , clopidogrel , percutaneous coronary intervention , disease , myocardial infarction

To evaluate the side effects of two antiplatelet agents - ticagrelor and eptifibatide - in mice with experimentally-induced inflammatory bowel disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research